Get the Stockscreener App
24.55
2.33%
0.56
Biodesix Inc stock is traded at $24.55, with a volume of 9,901.
It is up +2.33% in the last 24 hours and down -11.37% over the past month.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
See More
Previous Close:
$23.99
Open:
$23.92
24h Volume:
9,901
Relative Volume:
0.10
Market Cap:
$259.03M
Revenue:
$96.10M
Net Income/Loss:
$-31.96M
P/E Ratio:
-6.0968
EPS:
-4.0267
Net Cash Flow:
$-25.27M
1W Performance:
-4.21%
1M Performance:
-11.37%
6M Performance:
+93.92%
1Y Performance:
+230.86%
1-Day Range:
$23.84
$24.57
1-Week Range:
$23.65
$26.64
52-Week Range:
$5.26
$31.97
Biodesix Inc Stock (BDSX) Company Profile
Name
Biodesix Inc
Sector
Industry
Phone
303-417-0500
Address
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
24.55 | 259.03M | 96.10M | -31.96M | -25.27M | -4.0267 |
TMO
Thermo Fisher Scientific Inc
|
693.44 | 256.40B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
231.61 | 162.82B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
402.40 | 58.00B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
176.39 | 49.73B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
270.11 | 44.46B | 16.63B | 1.39B | 2.12B | 8.0674 |
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-25-26 | Initiated | Roth Capital | Buy |
| Jun-15-26 | Initiated | H.C. Wainwright | Buy |
| Feb-27-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-26-24 | Initiated | Craig Hallum | Buy |
| May-13-24 | Initiated | TD Cowen | Buy |
| May-03-24 | Initiated | Lake Street | Buy |
| Nov-17-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-23-20 | Initiated | BTIG Research | Buy |
| Nov-23-20 | Initiated | Canaccord Genuity | Buy |
| Nov-23-20 | Initiated | Morgan Stanley | Overweight |
| Nov-23-20 | Initiated | William Blair | Outperform |
View All
Biodesix Inc Stock (BDSX) Latest News
Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026 - GlobeNewswire Inc.
Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus - Zacks Investment Research
Converting 1,360 stock units leaves Biodesix (BDSX) chairman with 26,743 shares held directly. - Stock Titan
Biodesix Inc (NASDAQ: BDSX) Stock Price, News & Analysis - kalkine.ca
A Look at Biodesix Inc (BDSX) After 3.5% Gain -- GF Value $21.14 vs Price $26.96 - GuruFocus
Opaleye Management Inc. Cuts Position in Biodesix, Inc. $BDSX - marketbeat.com
Biodesix: Growing Fast While Trading Below Many Diagnostics Peers (NASDAQ:BDSX) - Seeking Alpha
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Recommendation of "Moderate Buy" by Analysts - marketbeat.com
BlackRock Inc. Invests $970,000 in Biodesix, Inc. $BDSX - marketbeat.com
Biodesix to Participate in Upcoming Investor Conferences - The Manila Times
Biodesix to Participate in Upcoming Investor Conferences - Moomoo
BioDesix (NASDAQ:BDSX) Passes Minervini Trend Template but Setup Quality Remains Weak - ChartMill
What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Biodesix Inc (BDSX) Stock Up 9.0% but GF Value Says Overvalued -- GF Score: 51/100 - GuruFocus
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect? - qz.com
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? - The Globe and Mail
Biodesix (BDSX) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Stock Loses 5.91% in the Latest SessionCEO Earnings Statement - vinanet.vn
Biodesix (BDSX) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Stock Loses 5.91% in the Latest SessionEarnings Revision Report - dars.gov.et
Biodesix (BDSX) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Stock Loses 5.91% in the Latest SessionFinancial Health Score - dars.gov.et
Biodesix (BDSX) Results Check: The Bottom-Line Figure Beats Its Comparison; After Earnings: The Market Price Declines 3.91% in Latest TradingGuidance Accuracy Score - vinanet.vn
Biodesix (BDSX) Results Check: The Bottom-Line Figure Beats Its Comparison; After Earnings: The Market Price Declines 3.91% in Latest TradingMargin Expansion Trends - dars.gov.et
46,989 Shares in Biodesix, Inc. $BDSX Purchased by GSA Capital Partners LLP - MarketBeat
AIGH Capital Management LLC Acquires New Stake in Biodesix, Inc. $BDSX - MarketBeat
Biodesix (BDSX) Edges Higher at $24.0 as Bulls Defend Key SupportVol Target Rebalance - vinanet.vn
Walleye Capital LLC Makes New $1.68 Million Investment in Biodesix, Inc. $BDSX - MarketBeat
Sei Investments Co. Makes New Investment in Biodesix, Inc. $BDSX - MarketBeat
Biodesix (BDSX) Edges Higher at $24.0 as Bulls Defend Key SupportTRIN Signal - dars.gov.et
Biodesix Stock Price Forecast. Should You Buy BDSX? - StockInvest.us
BDSX Q2 2026 Earnings: EPS Beats Estimates by 22.85% as Loss NarrowsEarnings Preview - vinanet.vn
BDSX | Biodesix, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Biodesix director Jack Schuler buys company stock, valued at $366,991 By Investing.com - Investing.com India
Biodesix director Jack Schuler buys company stock, valued at $366,991 By Investing.com - Investing.com Australia
Biodesix director Jack Schuler buys company stock, valued at $366,991 By Investing.com - Investing.com Nigeria
Biodesix director Jack Schuler buys company stock, valued at $366,991 - Investing.com
Biodesix director Jack Schuler buys company stock, valued at $366,991 - Investing.com
BDSX Q2 2026 Earnings: Narrower Loss Beats Estimates as Shares Dip 1.78Earnings Yield Spread - Vinanet
Biodesix (NASDAQ:BDSX) Director Jack Schuler Buys 15,000 Shares of Stock - MarketBeat
Biodesix Insider Bought Shares Worth $366,992, According to a Recent SEC Filing - marketscreener.com
Biodesix Inc (BDSX) major holder Jack W. Schuler buys 15,000 shares - Stock Titan
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Biodesix Insider Bought Shares Worth $366,992, According to a Recent SEC Filing - Yahoo Finance
Biodesix director Jack Schuler buys $665,940 in company stock By Investing.com - Investing.com Australia
Biodesix (NASDAQ:BDSX) Director Jack Schuler Purchases 13,700 Shares of Stock - MarketBeat
Insider Buying: Biodesix (NASDAQ:BDSX) Director Purchases 13,900 Shares - MarketBeat
Biodesix director Jack Schuler buys $665,940 in company stock By Investing.com - Investing.com Canada
Biodesix director Jack Schuler buys $665,940 in company stock - Investing.com India
Biodesix director Jack Schuler buys $665,940 in company stock - Investing.com
Biodesix director Jack Schuler buys $665,940 in company stock - Investing.com
Biodesix at Canaccord Genuity conference: growth, margins in focus By Investing.com - Investing.com Nigeria
Biodesix (BDSX) major holder Jack W. Schuler adds shares via trusts - Stock Titan
Biodesix Inc Stock (BDSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biodesix Inc Stock (BDSX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SCHULER JACK W | Emeritus Director |
Aug 11 '26 |
Buy |
24.01 |
13,700 |
328,911 |
540,810 |
| SCHULER JACK W | Emeritus Director |
Aug 10 '26 |
Buy |
24.25 |
13,900 |
337,029 |
527,110 |
| O'Kane Kieran | Chief Commercial Officer |
Feb 23 '26 |
Sale |
12.78 |
535 |
6,835 |
9,819 |
| Cowie Robin Harper | CFO, Sec'y & Treasurer |
Feb 23 '26 |
Sale |
12.78 |
535 |
6,835 |
16,231 |
| Vazquez Chris | Chief Accounting Officer |
Feb 23 '26 |
Sale |
12.78 |
211 |
2,696 |
1,586 |
| Hutton Scott | President & CEO |
Feb 23 '26 |
Sale |
12.78 |
1,490 |
19,036 |
48,767 |
| Hutton Scott | Officer |
Feb 23 '26 |
Proposed Sale |
12.77 |
1,490 |
19,027 |
0 |
| Pestano Gary Anthony | Chief Development Officer |
Feb 23 '26 |
Sale |
12.78 |
556 |
7,103 |
10,359 |
| O'Kane Kieran | Chief Commercial Officer |
Feb 10 '26 |
Sale |
10.08 |
584 |
5,889 |
8,885 |
| Vazquez Chris | Chief Accounting Officer |
Feb 10 '26 |
Sale |
10.08 |
101 |
1,018 |
1,234 |
0.42%
7.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):